Vera Bril

List of Publications by Year
in descending order

279 papers	16,676 citations	26567 56 h-index	18606 119 g-index
281 all docs	281 docs citations	281 times ranked	10351 citing authors

#	Article	IF	Citations
1	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.3	9
2	Myasthenia gravis in pregnancy: Systematic review and case series. Obstetric Medicine, 2022, 15, 108-117.	0.5	16
3	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	1.2	5
4	Pilot study of a novel transmembranous electromyography device for assessment of oral cavity and oropharyngeal muscles. Muscle and Nerve, 2022, 65, 303-310.	1.0	2
5	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	4.9	41
6	Electrodiagnostic evaluation in diabetic neuropathy. , 2022, , 35-45.		1
7	THE SENSITIVITY AND SPECIFICITY OF SPLIT HAND INDEX USING MUSCLE SONOGRAPHY. Canadian Journal of Neurological Sciences, 2022, , 1-16.	0.3	0
8	Orthostatic blood pressure changes and diabetes duration. Journal of Diabetes and Its Complications, 2022, 36, 108169.	1.2	2
9	Analysis of relapse by inflammatory Raschâ€built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2022, 27, 159-165.	1.4	3
10	Clinical profile and multidisciplinary needs of patients with neuromuscular disorders transitioning from paediatric to adult care. Neuromuscular Disorders, 2022, 32, 206-212.	0.3	0
11	Polyneuropathy Quality Measurement Set. Neurology, 2022, 98, 22-30.	1.5	0
12	Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Neurology, 2022, 98, 31-43.	1.5	64
13	Temporal Dispersion and Duration of the Distal Compound Muscle Action Potential Do Not Distinguish Diabetic Sensorimotor Polyneuropathy From Chronic Inflammatory Demyelinating Polyneuropathy. Frontiers in Neurology, 2022, 13, 872762.	1.1	1
14	Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs, 2022, 82, 865-887.	4.9	36
15	An update on the use of immunoglobulins as treatment for myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 703-715.	1.3	2
16	Retrospective study on the safety of <scp>COVID</scp>â€19 vaccination in myasthenia gravis. Muscle and Nerve, 2022, 66, 558-561.	1.0	10
17	Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865.	1.5	97
18	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. Clinical Neurophysiology, 2021, 132, 226-231.	0.7	4

#	Article	IF	Citations
19	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107798.	1.2	10
20	Fasciculation frequency at the biceps <scp>brachii</scp> and brachialis muscles is associated with <scp>amyotrophic lateral sclerosis</scp> disease burden and activity. Muscle and Nerve, 2021, 63, 204-208.	1.0	7
21	Performance of different criteria for refractory myasthenia gravis. European Journal of Neurology, 2021, 28, 1375-1384.	1.7	9
22	Chronic immunoglobulin maintenance therapy in myasthenia gravis. European Journal of Neurology, 2021, 28, 639-646.	1.7	27
23	Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.3	7
24	The complex association between pain and neuropathy. Muscle and Nerve, 2021, 63, 538-545.	1.0	0
25	Thymoma pathology and myasthenia gravis outcomes. Muscle and Nerve, 2021, 63, 868-873.	1.0	11
26	Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders. Canadian Journal of Neurological Sciences, 2021, , 1-7.	0.3	2
27	Treatment Approaches for Atypical CIDP. Frontiers in Neurology, 2021, 12, 653734.	1.1	9
28	Telephone consultation for myasthenia gravis care during the COVID â€19 pandemic: Assessment of a novel virtual myasthenia gravis index. Muscle and Nerve, 2021, 63, 831-836.	1.0	9
29	Emerging drugs for the treatment of myasthenia gravis. Expert Opinion on Emerging Drugs, 2021, 26, 259-270.	1.0	6
30	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. Diabetes Care, 2021, 44, 2107-2114.	4.3	28
31	Clinical profile and impact of comorbidities in patients with veryâ€lateâ€onset myasthenia gravis. Muscle and Nerve, 2021, 64, 462-466.	1.0	13
32	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	4.9	194
33	Analgesic effect of perineural local anesthetics, steroids, and conventional medical management for trauma and compression-related peripheral neuropathic pain: a retrospective cohort study. Pain Reports, 2021, 6, e945.	1.4	2
34	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 839-850.	1.3	2
35	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2021, 132, 2184-2190.	0.7	3
36	Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy. Current Diabetes Reviews, 2021, 17, .	0.6	1

#	Article	IF	Citations
37	Patientâ€reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. European Journal of Neurology, 2020, 27, 196-203.	1.7	11
38	Chronic stress, depression and personality type in patients with myasthenia gravis. European Journal of Neurology, 2020, 27, 204-209.	1.7	14
39	Quantitative sonographic evaluation of muscle thickness and fasciculation prevalence in healthy subjects. Muscle and Nerve, 2020, 61, 234-238.	1.0	13
40	The utility of a single simple question in the evaluation of patients with nondiabetic polyneuropathy. Muscle and Nerve, 2020, 61, 526-529.	1.0	4
41	Important advances in neuromuscular research in 2019. Lancet Neurology, The, 2020, 19, 14-16.	4.9	1
42	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. Journal of the Peripheral Nervous System, 2020, 25, 230-237.	1.4	15
43	Patient-acceptable symptom states in myasthenia gravis. Neurology, 2020, 95, e1617-e1628.	1.5	33
44	Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neuro-Oncology Advances, 2020, 2, i141-i149.	0.4	18
45	Superiority of sonographic evaluation of contracted versus relaxed muscle thickness in motor neuron diseases. Clinical Neurophysiology, 2020, 131, 1480-1486.	0.7	10
46	Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis. European Journal of Neurology, 2020, 27, 2286-2291.	1.7	11
47	New insights into very-late-onset myasthenia gravis. Nature Reviews Neurology, 2020, 16, 299-300.	4.9	8
48	Prospective study of stress, depression and personality in myasthenia gravis relapses. BMC Neurology, 2020, 20, 261.	0.8	9
49	Novel Treatments in Myasthenia Gravis. Frontiers in Neurology, 2020, 11, 538.	1.1	54
50	Electrophysiological Responsiveness to Long-Term Therapy in Chronic Inflammatory Demyelinating Polyneuropathy: Case Report. Case Reports in Neurology, 2020, 12, 40-44.	0.3	3
51	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. Diabetes Care, 2020, 43, 1829-1835.	4.3	40
52	Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness. Journal of Neuromuscular Diseases, 2020, 7, 297-300.	1.1	8
53	Split-hand phenomenon in motor neuron diseases: Sonographic assesment of muscle thickness. Clinical Neurophysiology, 2020, 131, 1721-1725.	0.7	11
54	Congenital myasthenic syndromeâ€“associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner. JCI Insight, 2020, 5, .	2.3	15

#	Article	IF	Citations
55	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	4
56	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107397.	1.2	8
57	Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment. Canadian Journal of Neurological Sciences, 2019, 46, 762-766.	0.3	1
58	European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders. Muscle and Nerve, 2019, 60, 748-752.	1.0	2
59	Current pharmacotherapeutic options for myasthenia gravis. Expert Opinion on Pharmacotherapy, 2019, 20, 2295-2303.	0.9	20
60	Evidence of smallâ€fiber neuropathy in neurofibromatosis type 1. Muscle and Nerve, 2019, 60, 673-678.	1.0	9
61	Muscle thickness measured by ultrasound is reduced in neuromuscular disorders and correlates with clinical and electrophysiological findings. Muscle and Nerve, 2019, 60, 687-692.	1.0	20
62	A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology, 2019, 81, 223-230.	0.6	23
63	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e590.	3.1	37
64	Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity. Canadian Journal of Neurological Sciences, 2019, 46, 735-741.	0.3	4
65	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	1.4	17
66	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	1.4	13
67	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. Journal of Diabetes and Its Complications, 2019, 33, 547-549.	1.2	1
68	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.5	169
69	Acute Intermittent Porphyria: A Report of 3 Cases with Neuropathy. Case Reports in Neurology, 2019, 11, 32-36.	0.3	10
70	Estimating GFR by Serum Creatinine, Cystatin C, and Î²2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.4	12
71	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Renal Failure, 2019, 41, 427-433.	0.8	4
72	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 41.	18.1	692

#	Article	IF	Citations
73	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. Canadian Journal of Neurological Sciences, 2019, 46, 337-341.	0.3	4
74	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	2.1	15
75	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	2.2	12
76	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.3	1
77	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	1.2	21
78	Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain. Canadian Journal of Neurological Sciences, 2019, 46, 79-82.	0.3	6
79	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	2.2	15
80	EQâ€5Dâ€5L and SFâ€6D health utility index scores in patients with myasthenia gravis. European Journal of Neurology, 2019, 26, 452-459.	1.7	12
81	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	4.3	16
82	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.3	3
83	Sex differences in neuropathic pain intensity in diabetes. Journal of the Neurological Sciences, 2018, 388, 103-106.	0.3	38
84	Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology, 2018, 90, e1425-e1434.	1.5	86
85	Muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique. Neuromuscular Disorders, 2018, 28, 450-453.	0.3	14
86	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	4.3	13
87	Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle and Nerve, 2018, 58, 197-203.	1.0	33
88	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	1.2	5
89	High frequency of MGUS in DSP. Muscle and Nerve, 2018, 57, 1018-1021.	1.0	0
90	The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle and Nerve, 2018, 57, 240-244.	1.0	27

#	Article	IF	Citations
91	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. Clinical Neurophysiology, 2018, 129, 122-126.	0.7	8
92	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. European Journal of Neurology, 2018, 25, 484-490.	1.7	23
93	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	4.9	193
94	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	4.3	17
95	Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. Blood Research, 2018, 53, 172.	0.5	5
96	046â€...Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A19.2-A19.	0.9	0
97	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	4.3	37
98	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	0.7	7
99	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	1.2	22
100	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.5	6
101	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia, 2018, 61, 1856-1861.	2.9	103
102	Quantitative sonographic assessment of myotonia. Muscle and Nerve, 2018, 57, 146-149.	1.0	7
103	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	2.3	38
104	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	1.1	13
105	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle and Nerve, 2017, 55, 166-170.	1.0	27
106	Peripheral nerve highâ€resolution ultrasound in diabetes. Muscle and Nerve, 2017, 55, 171-178.	1.0	64
107	Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000251.	1.2	15
108	Selective or predominant triceps muscle weakness in Africanâ€“American patients with myasthenia gravis. Neuromuscular Disorders, 2017, 27, 646-649.	0.3	6

#	Article	IF	Citations
109	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. Neurology, 2017, 88, 2294-2301.	1.5	95
110	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	1.2	37
111	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.3	12
112	Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 136-154.	4.3	1,452
113	Electrophysiological testing is correlated with myasthenia gravis severity. Muscle and Nerve, 2017, 56, 445-448.	1.0	19
114	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. Journal of the Neurological Sciences, 2017, 372, 223-227.	0.3	13
115	Neurofibromatosis Clinic: A Report on Patient Demographics and Evaluation of the Clinic. Canadian Journal of Neurological Sciences, 2017, 44, 577-588.	0.3	5
116	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	4.9	472
117	Rare disease levels of evidence. Neurology, 2017, 89, 988-989.	1.5	0
118	High-Dose Subcutaneous Immunoglobulin in Patients With Multifocal Motor Neuropathy. Journal of Infusion Nursing, 2017, 40, 305-312.	1.2	8
119	Myasthenia Gravis Impairment Index. Neurology, 2017, 89, 2357-2364.	1.5	35
120	Recording Fewer Than 20 Potential Pairs With SFEMG May Suffice for the Diagnosis of Myasthenia Gravis. Journal of Clinical Neurophysiology, 2017, 34, 408-412.	0.9	5
121	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. Journal of Diabetes and Its Complications, 2017, 31, 1066-1073.	1.2	26
122	GamunexÂ® in Guillain-BarrÃ© Syndrome: A Postmarketing, Retrospective, Observational Study. Canadian Journal of Neurological Sciences, 2017, 44, 711-717.	0.3	2
123	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetologia, 2017, 60, 2529-2531.	2.9	14
124	The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS ONE, 2017, 12, e0171597.	1.1	21
125	Ultrasound in Neuromuscular Disorders. Journal of Clinical Neurophysiology, 2016, 33, 80-85.	0.9	13
126	International clinimetric evaluation of the MGâ€QOL15, resulting in slight revision and subsequent validation of the MGâ€QOL15r. Muscle and Nerve, 2016, 54, 1015-1022.	1.0	85

#	Article	IF	Citations
127	Reference values for ultrasonograpy of peripheral nerves. Muscle and Nerve, 2016, 53, 538-544.	1.0	66
128	Study protocol for a pilot, randomised, double-blinded, placebo controlled trial of perineural local anaesthetics and steroids for chronic post-traumatic neuropathic pain in the ankle and foot: the PREPLANS study. BMJ Open, 2016, 6, e012293.	0.8	6
129	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 298-307.	2.4	25
130	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials, 2016, 17, 345.	0.7	21
131	The genomic landscape of schwannoma. Nature Genetics, 2016, 48, 1339-1348.	9.4	124
132	The Perfect Clinical Trial. International Review of Neurobiology, 2016, 127, 27-41.	0.9	7
133	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology, 2016, 127, 3294-3297.	0.7	6
134	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.3	11
135	Development and validation of the Myasthenia Gravis Impairment Index. Neurology, 2016, 87, 879-886.	1.5	43
136	Infusing IVIG through Community Care Access Services in Patients with CIDP. Canadian Journal of Neurological Sciences, 2016, 43, 326-328.	0.3	0
137	Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve, 2016, 53, 862-865.	1.0	18
138	Construction and validation of the chronic acquired polyneuropathy patientâ€reported index (CAPâ€PRI): A diseaseâ€specific, healthâ€related qualityâ€ofâ€life instrument. Muscle and Nerve, 2016, 54, 9-17.	1.0	17
139	Subcutaneous immunoglobulin for treatment of multifocal motor neuropathy. Muscle and Nerve, 2016, 54, 856-863.	1.0	20
140	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular Diabetology, 2016, 15, 14.	2.7	29
141	The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. Journal of Diabetes and Its Complications, 2016, 30, 1401-1407.	1.2	43
142	Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. Neurodegenerative Disease Management, 2016, 6, 237-247.	1.2	2
143	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.5	106
144	Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle and Nerve, 2016, 53, 872-876.	1.0	14

#	Article	IF	Citations
145	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 716-722.	1.2	20
146	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. Diabetes Care, 2016, 39, e67-e68.	4.3	19
147	Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders, 2016, 26, 41-46.	0.3	90
148	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. PLoS ONE, 2016, 11, e0165731.	1.1	33
149	Gelsolin Familial Amyloidosis Peripheral Neuropathy in Canada: A Case Report. Canadian Journal of Neurological Sciences, 2015, 42, 353-355.	0.3	5
150	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	1.4	27
151	Grip strength comparison in immuneâ€mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	1.4	28
152	Safety and efficacy of ranirestat in patients with mildâ€toâ€moderate diabetic sensorimotor polyneuropathy. Journal of the Peripheral Nervous System, 2015, 20, 363-371.	1.4	21
153	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	1.4	30
154	Followâ€up nerve conduction studies in CIDP after treatment with IGIVâ€C: Comparison of patients with and without subsequent relapse. Muscle and Nerve, 2015, 52, 498-502.	1.0	20
155	Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale. Journal of Neuromuscular Diseases, 2015, 2, 301-311.	1.1	11
156	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	1.1	8
157	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. PLoS ONE, 2015, 10, e0142309.	1.1	37
158	Peripheral Nerve Ultrasound in Small Fiber Polyneuropathy. Ultrasound in Medicine and Biology, 2015, 41, 2820-2826.	0.7	28
159	Diabetic Neuropathies. Seminars in Neurology, 2015, 35, 424-430.	0.5	21
160	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. Neuroepidemiology, 2015, 44, 108-113.	1.1	20
161	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. Expert Review of Clinical Immunology, 2015, 11, 537-546.	1.3	13
162	Choosing drugs for the treatment of diabetic neuropathy. Expert Opinion on Pharmacotherapy, 2015, 16, 1805-1814.	0.9	6

#	Article	IF	Citations
163	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. Diabetes Care, 2015, 38, 838-843.	4.3	150
164	InÂVivo Corneal Confocal Microscopy and Prediction ofÂFuture-Incident Neuropathy in Type 1 Diabetes: AÂPreliminaryÂLongitudinal Analysis. Canadian Journal of Diabetes, 2015, 39, 390-397.	0.4	57
165	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	1.1	9
166	Excessive Daytime Sleepiness in Patients with Myasthenia Gravis. Journal of Neuromuscular Diseases, 2015, 2, 93-97.	1.1	1
167	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. PLoS ONE, 2014, 9, e86515.	1.1	72
168	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes â€“ An Observational Study. PLoS ONE, 2014, 9, e89344.	1.1	29
169	Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes. Expert Review of Clinical Immunology, 2014, 10, 1659-1665.	1.3	31
170	Prevalence of Muscle Cramps in Patients With Diabetes: Table 1. Diabetes Care, 2014, 37, e17-e18.	4.3	21
171	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? Diabetes Care 2014;37:1418â€“1424. Diabetes Care, 2014, 37, e242-e242.	4.3	1
172	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. Diabetes Care, 2014, 37, 1418-1424.	4.3	105
173	Changing outcome in inflammatory neuropathies. Neurology, 2014, 83, 2124-2132.	1.5	89
174	Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study. Orphanet Journal of Rare Diseases, 2014, 9, 214.	1.2	26
175	Neuromuscular Complications of Diabetes Mellitus. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 531-544.	0.4	12
176	Characteristics of muscle cramps in patients with polyneuropathy. Neuromuscular Disorders, 2014, 24, 671-676.	0.3	8
177	Comparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patients. Journal of Neurology, 2014, 261, 1485-1491.	1.8	13
178	Incat disability score: A critical analysis of its measurement properties. Muscle and Nerve, 2014, 50, 164-169.	1.0	41
179	Electrophysiologic testing in diabetic neuropathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 235-248.	1.0	32
180	Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trial. Muscle and Nerve, 2014, 49, 661-665.	1.0	50

#	Article	IF	Citations
181	Ischaemia due to a vascular malformation causing focal myositis. BMJ Case Reports, 2014, 2014, bcr2013202442-bcr2013202442.	0.2	5
182	A Conceptual Framework for Evaluating Impairments in Myasthenia Gravis. PLoS ONE, 2014, 9, e98089.	1.1	23
183	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. PLoS ONE, 2014, 9, e106995.	1.1	14
184	Performance of individual items of the quantitative myasthenia gravis score. Neuromuscular Disorders, 2013, 23, 413-417.	0.3	18
185	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2013, 36, 3684-3690.	4.3	63
186	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. Journal of Diabetes and Its Complications, 2013, 27, 240-242.	1.2	15
187	Neuropathy. Canadian Journal of Diabetes, 2013, 37, S142-S144.	0.4	19
188	Diagnosis of Painful Diabetic Neuropathy. , 2013, , 27-34.		0
189	Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle and Nerve, 2013, 47, 510-514.	1.0	32
190	Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 94-97.	0.9	28
191	Association of social support with quality of life in patients with polyneuropathy. Journal of the Peripheral Nervous System, 2013, 18, 37-43.	1.4	10
192	Comparison of diabetes patients with â€œdemyelinatingâ€•diabetic sensorimotor polyneuropathy to those diagnosed with <scp>CIDP</scp>. Brain and Behavior, 2013, 3, 656-663.	1.0	21
193	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. Diabetes Care, 2013, 36, 2748-2755.	4.3	83
194	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. PLoS ONE, 2013, 8, e58783.	1.1	58
195	Detection of Diabetic Sensorimotor Polyneuropathy by Corneal Confocal Microscopy in Type 1 Diabetes. Diabetes Care, 2012, 35, 821-828.	4.3	177
196	FcÎ³ Receptor Polymorphisms Do Not Predict Response to Intravenous Immunoglobulin in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2012, 14, 1-6.	0.3	3
197	The Quantitative Myasthenia Gravis Score. Journal of Clinical Neuromuscular Disease, 2012, 13, 201-205.	0.3	46
198	Variables associated with corneal confocal microscopy parameters in healthy volunteers: implications for diabetic neuropathy screening. Diabetic Medicine, 2012, 29, e297-303.	1.2	62

#	Article	IF	Citations
199	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. Diabetes Care, 2012, 35, 2575-2579.	4.3	92
200	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. Diabetes Research and Clinical Practice, 2012, 97, e37-e40.	1.1	12
201	IVIG and PLEX in the treatment of myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 1-6.	1.8	21
202	Diabetic Neuropathy and Axon Reflex-Mediated Neurogenic Vasodilatation in Type 1 Diabetes. PLoS ONE, 2012, 7, e34807.	1.1	22
203	Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle and Nerve, 2012, 45, 648-652.	1.0	18
204	Treatments for diabetic neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 22-27.	1.4	54
205	Suralâ€toâ€radial amplitude ratio in the diagnosis of diabetic sensorimotor polyneuropathy. Muscle and Nerve, 2012, 45, 126-127.	1.0	15
206	Evaluation of Proxy Tests for SFSN: Evidence for Mixed Small and Large Fiber Dysfunction. PLoS ONE, 2012, 7, e42208.	1.1	14
207	How sensitive is the case definition for diabetic sensorimotor polyneuropathy to the use of different symptoms, signs, and nerve conduction parameters in Type 1 diabetes?. Diabetes Research and Clinical Practice, 2011, 92, e16-e19.	1.1	6
208	Dorsal versus ventral monofilament testing of the great toe for the identification of diabetic sensorimotor polyneuropathy. Diabetes Research and Clinical Practice, 2011, 93, e71-e73.	1.1	3
209	Reproducibility of in vivo corneal confocal microscopy as a novel screening test for early diabetic sensorimotor polyneuropathy. Diabetic Medicine, 2011, 28, 1253-1260.	1.2	135
210	Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/Metabolism Research and Reviews, 2011, 27, 620-628.	1.7	359
211	Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology, 2011, 76, 2017-2023.	1.5	273
212	Evidence-based guideline: Treatment of painful diabetic neuropathy [RETIRED]. Neurology, 2011, 76, 1758-1765.	1.5	561
213	Electrophysiologic correlations with clinical outcomes in CIDP. Muscle and Nerve, 2010, 42, 492-497.	1.0	56
214	Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. Journal of the Peripheral Nervous System, 2010, 15, 208-215.	1.4	41
215	Shortâ€term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1â€year placebo cohort analysis. Diabetic Medicine, 2010, 27, 1271-1279.	1.2	27
216	Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination. Diabetes Care, 2010, 33, 1549-1554.	4.3	80

#	Article	IF	Citations
217	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2010, 67, 802.	4.9	99
218	Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2009, 32, 1256-1260.	4.3	88
219	Current and future immunotherapy in myasthenia gravis. Future Neurology, 2009, 4, 745-759.	0.9	1
220	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle and Nerve, 2009, 39, 448-455.	1.0	42
221	Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetic Medicine, 2009, 26, 240-246.	1.2	153
222	Improvement of Motor Nerve Conduction Velocity in Diabetic Rats Requires Normalization of the Polyol Pathway Metabolites Flux. Journal of Pharmacological Sciences, 2009, 109, 203-210.	1.1	12
223	Surrogate therapeutic outcome measures in patients with myasthenia gravis. Muscle and Nerve, 2008, 37, 172-176.	1.0	12
224	IVIG Treatment for Myasthenia Gravis. Annals of the New York Academy of Sciences, 2008, 1132, 264-270.	1.8	23
225	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, The, 2008, 7, 136-144.	4.9	582
226	Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Reduces Sorbitol Levels and Improves Motor Nerve Conduction Velocity in Streptozotocin-Diabetic Rats. Journal of Pharmacological Sciences, 2008, 107, 231-237.	1.1	41
227	Long-Term Treatment With Ranirestat (AS-3201), a Potent Aldose Reductase Inhibitor, Suppresses Diabetic Neuropathy and Cataract Formation in Rats. Journal of Pharmacological Sciences, 2008, 107, 340-348.	1.1	39
228	A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2008, 9, 352-355.	0.3	44
229	IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology, 2007, 68, 837-841.	1.5	255
230	Management of Myasthenia Gravis: Does Thymectomy Provide Benefit over Medical Therapy Alone?. , 2007, , 463-468.		0
231	Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis. Muscle and Nerve, 2006, 33, 694-696.	1.0	28
232	Diagnostic Tools for Diabetic Sensorimotor Polyneuropathy. Current Diabetes Reviews, 2006, 2, 353-361.	0.6	9
233	Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2006, 29, 68-72.	4.3	126
234	Validation of a Novel Point-of-Care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2006, 29, 2023-2027.	4.3	53

#	Article	IF	Citations
235	A Comparison of Electrodiagnostic Tests in Ocular Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2005, 6, 109-113.	0.3	28
236	Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy. Muscle and Nerve, 2005, 32, 619-625.	1.0	56
237	Emerging Therapies for Diabetic Neuropathy: A Clinical Overview. Current Diabetes Reviews, 2005, 1, 271-280.	0.6	11
238	Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C Î²-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clinical Therapeutics, 2005, 27, 1164-1180.	1.1	161
239	Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics, 2005, 27, 1278-1294.	1.1	162
240	A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfusion and Apheresis Science, 2005, 33, 317-324.	0.5	30
241	Diabetic Neuropathies: A statement by the American Diabetes Association. Diabetes Care, 2005, 28, 956-962.	4.3	1,599
242	Low-Intensity Laser Therapy for Painful Symptoms of Diabetic Sensorimotor Polyneuropathy: A controlled trial. Diabetes Care, 2004, 27, 921-924.	4.3	69
243	Sural Nerve Sorbitol in Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2004, 27, 1160-1163.	4.3	12
244	Aldose Reductase Inhibition by AS-3201 in Sural Nerve From Patients With Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2004, 27, 2369-2375.	4.3	88
245	Cooling Detection Thresholds in the Assessment of Diabetic Sensory Polyneuropathy: Comparison of CASE IV and Medoc instruments. Diabetes Care, 2004, 27, 1674-1679.	4.3	42
246	Diabetic neuropathy: a review emphasizing diagnostic methods. Clinical Neurophysiology, 2003, 114, 1167-1175.	0.7	139
247	Impact of minimally invasive trans-cervical thymectomy on outcome in patients with myasthenia gravis. European Journal of Cardio-thoracic Surgery, 2003, 24, 677-683.	0.6	81
248	Validation of the Toronto Clinical Scoring System for Diabetic Polyneuropathy. Diabetes Care, 2002, 25, 2048-2052.	4.3	341
249	Comparison of sensory testing on different toe surfaces: Implications for neuropathy screening. Neurology, 2002, 59, 611-613.	1.5	24
250	Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy. Diabetes Care, 2002, 25, 565-569.	4.3	241
251	Prognostic significance of thymomas in patients with myasthenia gravis. Annals of Thoracic Surgery, 2002, 74, 1658-1662.	0.7	66
252	Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. Muscle and Nerve, 2002, 25, 212-217.	1.0	28

#	Article	IF	Citations
253	Diagnosis and management of diabetic neuropathy. Current Diabetes Reports, 2002, 2, 495-500.	1.7	32
254	Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabetic Medicine, 2002, 19, 661-666.	1.2	46
255	Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Research and Clinical Practice, 2001, 54, 115-128.	1.1	123
256	Status of Current Clinical Trials in Diabetic Polyneuropathy. Canadian Journal of Neurological Sciences, 2001, 28, 191-198.	0.3	18
257	Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic. Diabetes Care, 2001, 24, 250-256.	4.3	454
258	Glycemic Control Is Related to the Morphological Severity of Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2001, 24, 748-752.	4.3	54
259	Heart Rate Variability Measurement in Diabetic Neuropathy: Review of Methods. Diabetes Technology and Therapeutics, 2001, 3, 63-76.	2.4	59
260	Sensory nerve area measurements in patients with diabetic neuropathy. Electromyography and Clinical Neurophysiology, 2001, 41, 59-63.	0.2	1
261	Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2000, 23, 206-210.	1.0	21
262	Limits of the sympathetic skin response in patients with diabetic polyneuropathy. Muscle and Nerve, 2000, 23, 1427-1430.	1.0	26
263	NIS-LL: The Primary Measurement Scale for Clinical Trial Endpoints in Diabetic Peripheral Neuropathy. European Neurology, 1999, 41, 8-13.	0.6	120
264	Electrophysiological monitoring in clinical trials. , 1998, 21, 1368-1373.		95
265	Long-Term Clinical Outcome After Transcervical Thymectomy for Myasthenia Gravis. Annals of Thoracic Surgery, 1998, 65, 1520-1522.	0.7	96
266	The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology, 1998, 51, 1198-1200.	1.5	39
267	Glycemic Control Is Related to the Electrophysiologic Severity of Diabetic Peripheral Sensorimotor Polyneuropathy. Diabetes Care, 1998, 21, 1749-1752.	4.3	49
268	Comparison of a Neurothesiometer and Vibration in Measuring Vibration Perception Thresholds and Relationship to Nerve Conduction Studies. Diabetes Care, 1997, 20, 1360-1362.	4.3	50
269	POEMS syndrome in a 24-year-old man associated with vitamin B12 deficiency and a solitary lytic bone lesion. , 1997, 20, 1454-1456.		6
270	Single-fiber electromyography in diabetic peripheral polyneuropathy. , 1996, 19, 2-9.		52

#	Article	IF	Citations
271	Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study. Brain, 1996, 119, 1055-1066.	3.7	392
272	Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. Journal of Diabetes and Its Complications, 1995, 9, 170-176.	1.2	73
273	Complications of Sural Nerve Biopsy in Diabetic versus Non-Diabetic Patients. Canadian Journal of Neurological Sciences, 1994, 21, 34-37.	0.3	38
274	Role of Electrophysiological Studies in Diabetic Neuropathy. Canadian Journal of Neurological Sciences, 1994, 21, S8-S12.	0.3	28
275	Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle and Nerve, 1993, 16, 1293-1301.	1.0	68
276	Regeneration and Repair of Myelinated Fibers in Sural-Nerve Biopsy Specimens from Patients with Diabetic Neuropathy Treated with Sorbinil. New England Journal of Medicine, 1988, 319, 548-555.	13.9	321
277	Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.. Journal of Clinical Investigation, 1988, 81, 349-364.	3.9	197
278	Midbrain asterixis. Annals of Neurology, 1979, 6, 362-364.	2.8	41
279	Gastrointestinal Dysmotility as the First Manifestation of Myasthenia Gravis. Canadian Journal of Neurological Sciences, 0, , 1-7.	0.3	0